Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics, Inc. President and CEO Helen Torley, who is also a director, reported a series of option exercises and related stock sales in early February 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025.
On February 3–5, 2026, she exercised company stock options at an exercise price of $12.07 per share and sold the resulting common shares in multiple transactions at weighted average prices generally in the mid-to-high $70s per share, as detailed in the price ranges disclosed for each trade.
Following these transactions, she directly held 708,719 shares of Halozyme common stock and 201,923 options to purchase common stock, with the options originally granted on February 22, 2017 and exercisable over a four-year vesting schedule.
A shareholder of Halozyme Therapeutics, Inc. filed a Form 144 notice to sell 150,000 shares of common stock through J.P. Morgan Securities on the NASDAQ, with an approximate sale date of 02/03/2026. The filing lists an aggregate market value of $11,167,500 for these shares and notes that 117,597,000 shares of common stock were outstanding. The shares to be sold were acquired on 02/03/2026 via a stock option exercise paid in cash. The same shareholder previously sold multiple blocks of Halozyme common stock in November and December 2025, including 20,000-share sales on several November dates and 16,569 shares on 12/01/2025 with reported gross proceeds for each transaction.
Halozyme Therapeutics provides preliminary, unaudited estimates for its 2025 results, including total revenue between $1,385 million and $1,400 million. The company estimates 2025 royalties of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. These figures were shared in connection with 2026 financial guidance and remain subject to completion of year-end financial closing procedures.
Halozyme Therapeutics provides preliminary, unaudited estimates for its 2025 results, including total revenue between $1,385 million and $1,400 million. The company estimates 2025 royalties of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. These figures were shared in connection with 2026 financial guidance and remain subject to completion of year-end financial closing procedures.
Halozyme Therapeutics, Inc. reported that it has entered into a Transition and Release Agreement with its Senior Vice President and Chief Financial Officer, Nicole LaBrosse, in connection with her previously announced planned departure. She will continue as CFO until the earlier of the hiring of a new CFO, March 30, 2026, or an earlier date set by the company, after which she will leave to pursue another opportunity.
Under the agreement, Ms. LaBrosse is eligible to receive her 2025 annual bonus at 120% target-level individual performance, cash severance consistent with a termination not for cause, potential pro-rated 2026 bonus, accelerated vesting of certain equity awards if her separation occurs before February 28, 2026, and an extended one-year post-termination exercise window for vested stock options. If a Change in Control occurs within one year after her separation, all then-unvested options will vest, and the company will cover the cost of COBRA healthcare continuation for one year following her separation date.
Halozyme Therapeutics, Inc. is registering 219,336 shares of its common stock, par value $0.001 per share, for issuance upon exercise of stock options outstanding under the Elektrofi, Inc. 2015 Equity Incentive Plan, as amended. These options were assumed in connection with Halozyme’s acquisition of Elektrofi, Inc., which closed pursuant to a merger in which Elektrofi became a wholly owned subsidiary of Halozyme. The filing also confirms that Halozyme has incorporated a broad set of previously filed reports and describes its standard Delaware-law indemnification protections for directors and officers, including charter and bylaw provisions, individual indemnification agreements, and related insurance coverage.
Halozyme Therapeutics (HALO) insider activity: The President and CEO, who also serves as a director, exercised stock options and sold shares under a Rule 10b5-1 trading plan adopted on March 21, 2025.
Across November 10–12, 2025, the executive exercised 60,000 options at $8.11 per share (20,000 each day) and sold 60,000 shares in multiple tranches. Reported weighted average sales prices included $68.714 and $69.3 on November 10; $67.892, $68.795, and $69.731 on November 11; and $70.218, $71.089, and $71.667 on November 12. The sales reflect shares acquired from option exercises, with the underlying options having a ten‑year term expiring in February 2026.
Following the reported transactions, the executive beneficially owned 733,719 shares directly. Remaining options beneficially owned declined to 16,569 after these exercises.
Halozyme Therapeutics (HALO) reported an insider transaction by a director. On 11/10/2025, the director sold 2,000 shares of common stock at $68.48 per share under a Rule 10b5-1 trading plan adopted on May 29, 2025. Following the sale, the director beneficially owns 42,952 shares, held directly.
Halozyme Therapeutics completed a $1.5 billion convertible note financing, split between $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, including full exercise of the Initial Purchasers’ options.
The company received net proceeds of approximately $1.47 billion. It used about $182.7 million for capped call transactions and paid approximately $1.020 billion in cash to repurchase portions of its 2027 and 2028 convertible notes. The remaining proceeds are earmarked for general corporate purposes, potential acquisitions and strategic transactions, and potential future note repurchases or repayment at maturity.
The notes are convertible at an initial rate of 11.4683 shares per $1,000 (conversion price ~$87.20). The 2032 notes bear 0.875% interest, paid semi‑annually starting May 15, 2026; the 2031 notes bear no regular interest. Capped calls carry an initial cap price of $136.78 per share. Holders have customary conversion windows and protections, including Fundamental Change repurchase rights and Make‑Whole adjustments, under the new indentures.
Halozyme Therapeutics announced the pricing of two convertible senior note offerings to institutional investors under Rule 144A. The company plans to issue $650.0 million aggregate principal amount of notes due 2031 and $650.0 million due 2032. Initial purchasers received a 13-day option to buy up to an additional $100.0 million of each series. The notes are being offered only to persons reasonably believed to be qualified institutional buyers.
A press release with additional details was furnished as Exhibit 99.1.
Halozyme Therapeutics (HALO) amended its credit facility, extending and upsizing its revolving line to $750,000,000. The amended revolver now matures on the earlier of November 5, 2030 or a springing maturity date, with borrowings priced at Term SOFR or a base rate plus an applicable margin ranging from 0.25% to 1.25% for base rate loans and 1.25% to 2.25% for Term SOFR loans. As of November 5, 2025, outstanding borrowings were $0.
The company also announced proposed convertible offerings: $650.0 million aggregate principal amount of notes due 2031 and $650.0 million due 2032, with an expected 13‑day option for initial purchasers to buy up to an additional $100.0 million of each series. The credit agreement includes customary covenants, including a maximum consolidated net leverage ratio of 4.50 to 1.00 (temporarily increasing by 0.50 after a material acquisition) and a minimum consolidated interest coverage ratio of 3.00 to 1.00.